) recently announced the publication of results from a study
regarding its weight-loss drug, Qsymia. Results from the study
revealed that the weight loss arising from treatment with Qsymia
capsules CIV significantly reduced cholesterol, blood pressure
and triglycerides levels in obese and overweight patients
affected by one or more of these associated conditions.
Data from the study further revealed that significantly
greater improvements were observed in patients who lost at least
10% of their initial weight following treatment with Qsymia. The
primary endpoints of the study were percentage weight loss and
the proportion of patients who underwent at least 5% weight loss
after taking the drug. Data also revealed that treatment with
Qsymia resulted in significantly greater dose-related mean
percentage weight loss as opposed to placebo in the subgroups of
patients suffering from dyslipidemia and hypertension.
We note that the drug is already available in the US. Qsymia
was approved by the US Food and Drug Administration (FDA) in Jul
2012. The FDA cleared Qsymia as an adjunct to a healthy diet (low
on calories) and increased physical activity for chronic weight
management in obese (Body Mass Index, or BMI - 30 or more) or
overweight (BMI - 27 or more) adults suffering from at least one
weight-related co-morbid condition.
However the drug is yet to found favor with the European
regulatory authorities. In Oct 2012, the Committee for Medicinal
Products for Human Use (CHMP) of the European Medicines Agency
(EMA) did not recommend the approval of Qsiva (proposed trade
name of the drug in Europe).
We remind investors that apart from Qsymia, another
Arena Pharmaceuticals, Inc.
) Belviq, also received approval last year.
Vivus, a biopharmaceutical company, currently carries a Zacks
Rank #3 (Hold). Biopharma stocks, such as
Peregrine Pharmaceuticals, Inc
) are much more favorably placed and carry a Zacks Rank #1
ARENA PHARMA (ARNA): Free Stock Analysis
PEREGRINE PHARM (PPHM): Free Stock Analysis
TARGACEPT INC (TRGT): Free Stock Analysis
VIVUS INC (VVUS): Free Stock Analysis Report
To read this article on Zacks.com click here.